Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020

IMPORTANCE: Neuroendocrine neoplasms (NENs) have historically been grouped homogenously in clinical trials, despite their heterogeneity. Given the adoption of a more advanced pathologic classification system and drug licensure of several targeted therapies over the last decade, information is needed...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Satya, Du, Liping, Lee, Cody L., Arhin, Nina D., Chan, Jennifer A., Kohn, Elise C., Halperin, Daniel M., Berlin, Jordan, LaFerriere, Heather, Singh, Simron, Kunz, Pamela L., Dasari, Arvind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552059/
https://www.ncbi.nlm.nih.gov/pubmed/34705010
http://dx.doi.org/10.1001/jamanetworkopen.2021.31744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552059/
https://www.ncbi.nlm.nih.gov/pubmed/34705010
http://dx.doi.org/10.1001/jamanetworkopen.2021.31744

Ejemplares similares